Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Exelixis Inc
(NQ:
EXEL
)
26.66
+0.42 (+1.60%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Exelixis Inc
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Exelixis (EXEL) Q4 2023 Earnings Call Transcript
February 06, 2024
EXEL earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Recap: Exelixis Q4 Earnings
February 06, 2024
Via
Benzinga
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
February 06, 2024
From
Exelixis, Inc.
Via
Business Wire
Earnings Scheduled For February 6, 2024
February 06, 2024
Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion.
Via
Benzinga
Earnings Preview For Exelixis
February 05, 2024
Via
Benzinga
In the world of growth stocks, NASDAQ:EXEL shines as a value proposition.
February 05, 2024
NASDAQ:EXEL, a growth stock which is not overvalued.
Via
Chartmill
Breaking Down Exelixis: 7 Analysts Share Their Views
January 30, 2024
Via
Benzinga
NASDAQ:EXEL is showing good growth, while it is not too expensive.
December 21, 2023
Don't overlook EXELIXIS INC (NASDAQ:EXEL)—a stock with solid growth prospects and a reasonable valuation.
Via
Chartmill
6 Analysts Have This to Say About Exelixis
December 13, 2023
Via
Benzinga
NASDAQ:EXEL, a growth stock which is not overvalued.
November 29, 2023
Investors seeking growth at a reasonable cost should explore NASDAQ:EXEL.
Via
Chartmill
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
February 01, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
January 25, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024
January 23, 2024
From
Exelixis, Inc.
Via
Business Wire
Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study
January 23, 2024
Bristol Myers Squibb & Exelixis Inc revealed four-year follow-up results from CheckMate -9ER trial.
Via
Benzinga
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
January 22, 2024
From
Bristol Myers Squibb
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
January 22, 2024
Via
Benzinga
3 Top-Rated Biotech Stocks Wall Street Analysts Are Loving Now: January 2024
January 21, 2024
These top-rated biotech stocks are going to be in high demand in January and in every other month in 2024.
Via
InvestorPlace
European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets
January 18, 2024
From
Exelixis, Inc.
Via
Business Wire
3 Pharma Stocks Could Be the Pills Your Portfolio Needs
January 18, 2024
These large-cap pharma stocks offer growth and value with existing medicines, deep pipelines and reasonable valuations.
Via
InvestorPlace
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review
January 12, 2024
The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut.
Via
Investor's Business Daily
Topics
ETFs
Jim Cramer Likes This 'Well-Run' Airline, Says This Entertainment Stock Has 'Balance Sheet From Hell'
January 12, 2024
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Franco-Nevada Corporation (NYSE: FNV) is a "great diversified
Via
Benzinga
Don't overlook NASDAQ:EXEL—a stock with solid growth prospects and a reasonable valuation.
January 11, 2024
Investors should take note ofEXELIXIS INC (NASDAQ:EXEL), a growth stock that remains attractively priced.
Via
Chartmill
Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today?
January 08, 2024
Sunday, Exelixis Inc (NASDAQ: EXEL) provided financial guidance for fiscal year 2024 and delivered an
Via
Benzinga
Regeneron Slumps As Its Biggest Moneymaker Falls Short; Exelixis Dives On Guidance Woes
January 08, 2024
Shares of both skidded early Monday as the annual J.P. Morgan Healthcare Conferenced kicked off In San Francisco.
Via
Investor's Business Daily
Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024
January 07, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024
January 02, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023
December 07, 2023
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer
December 04, 2023
From
Exelixis, Inc.
Via
Business Wire
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma
December 04, 2023
From
Arcus Biosciences
Via
Business Wire
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment
November 29, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.